Inhibitory effects of combinations of trastuzumab and cytotoxic chemotherapy drugs in HER2-positive gastric cancer

References

• Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. 2014. Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population. Gastric Cancer. 17(1):34–42.
   Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. 2012. Treatment of HER2- positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 9:16–32
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 376 (9742): 687–697.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cross M, Dexter TM. 1991. Growth factors in development, transformation, and tumorigenesis. Cell. 64(2):271–280.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. 2008. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358(1): 36–46.
   PubMed Web of Science ®Google Scholar
• Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. 2007. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 59(6), 795–805.
   PubMed Web of Science ®Google Scholar
• Gong SJ, Jin CJ, Rha SY, Chung HC. 2004. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 214(2):215–224.
   PubMed Web of Science ®Google Scholar
• Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X. 2014. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 35(6):5315–5321.
   PubMedGoogle Scholar
• Hechtman JF, Polydorides AD. 2012. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 136:691–697.
   PubMed Web of Science ®Google Scholar
• Huang D, Lu N, Fan Q, Sheng W, Bu H, Jin X, Li G, Liu Y, Li X, Sun W, et al. 2013. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS One. 8(11):e80290.
   PubMed Web of Science ®Google Scholar
• Hung MC, Lau YK. 1999. Basic science of HER-2/neu: a review. Semin Oncol. 26 (4 Suppl 12). 51–59.
   PubMed Web of Science ®Google Scholar
• Kasprzyk PG, Song SU, Di Fiore PP, King CR. 1992. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies, Cancer Res. 52:2771–2776.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim HP, Kim YJ, Oh DY, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. 2008. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 32(1), 89–95.
   PubMed Web of Science ®Google Scholar
• Klapper LN, Waterman H, Sela M, Yarden Y. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60, 3384–3388.
   PubMed Web of Science ®Google Scholar
• Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al. 2015. Multicenter largescale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 18(4):691–697.
   PubMed Web of Science ®Google Scholar
• Li XL, Yi SQ, Xu JM, Zhang Y, Yingying-Feng, Chen W, Song ST. 2010. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest. 28(10):1038–1047.
   PubMed Web of Science ®Google Scholar
• Liu N, Zhu M, Linhai Y, et al. 2018. Increasing HER2 α2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways. Oncol Rep. 40(5):2997–3005.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. 2005. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol. 27(3), 681–685.
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. 2006. Herceptin: mechanisms of action and resistance. Cancer Lett. 232(2); 123–138.
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. 2020. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 17(1):33–48.
   PubMed Web of Science ®Google Scholar
• Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. 2005. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 117(3): 376–380.
   PubMed Web of Science ®Google Scholar
• Paik S, Burkhard E, Lippman ME. 1992. Clinical significance of erbB2 protein overexpression. Cancer Treat Res. 61:181–191.
   Google Scholar
• Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D, et al. 2014. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 14:823.
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. 2009. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 14:320–368.
   PubMed Web of Science ®Google Scholar
• Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herráez-Baranda LA, Xia F, Garg A, Shing M, Tabernero J. 2017. HELOISE: phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients With human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. Aug 1;35(22):2558–2567.
   PubMed Web of Science ®Google Scholar
• Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X. 2013. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 24(9): 2360–2364.
   Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al. 2011. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365:1273–1283.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783–792.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. 2016. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 27: v38–v49.
   PubMed Web of Science ®Google Scholar
• Sofia P, Arturo LB, Muaiad K, et al. 2014. Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res. Jan;34(1):301–306.
   Google Scholar
• Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, Kris R, Shiloh Y, Givol D, Schlessinger J. 1988. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res. 48(6):1517–1520.
   PubMed Web of Science ®Google Scholar
• Tortora G. 2011. Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011(43): 95–98.
   Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, et al. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. 2010. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 3:CD004064
   PubMed Web of Science ®Google Scholar
• Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, Yu D. 2019. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 183:111682.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, et al. 2018. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 50:768–779.
   Google Scholar